Business UpdateJun 8, 2026, 09:06 AM
MetaVia Presents Promising Obesity and Metabolic Data for DA-1726 and Vanoglipel
AI Summary
MetaVia Inc. presented new late-breaking data at the ADA 2026 Scientific Sessions highlighting its obesity and metabolic disease portfolio. Phase 1 results for DA-1726, a dual GLP1R/GCGR agonist, showed up to a 9.1% mean body weight reduction at Day 54 in obese adults. Preclinical data also supported combination treatment potential for vanoglipel (DA-1241), a GPR119 agonist, demonstrating synergistic effects in MASH and type 2 diabetes models when combined with other agents.
Key Highlights
- DA-1726 Phase 1, 48 mg cohort showed up to 9.1% mean body weight reduction by Day 54.
- DA-1726 demonstrated sustained exposure and dose-proportional PK.
- Vanoglipel combined with resmetirom showed synergistic weight loss (23.6% reduction) and hepatoprotective effects in preclinical MASH model.
- Vanoglipel combined with metformin achieved 16.3% body weight reduction and improved glycemic control in preclinical T2D model.
- DA-1726 is a novel GLP1R/GCGR dual agonist for obesity and MASH.
- Vanoglipel (DA-1241) is a GPR119 agonist for MASH and type 2 diabetes.
Price Impact
More from MTVA